254 related articles for article (PubMed ID: 27224915)
21. A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy.
Choi WW; Weisenburger DD; Greiner TC; Piris MA; Banham AH; Delabie J; Braziel RM; Geng H; Iqbal J; Lenz G; Vose JM; Hans CP; Fu K; Smith LM; Li M; Liu Z; Gascoyne RD; Rosenwald A; Ott G; Rimsza LM; Campo E; Jaffe ES; Jaye DL; Staudt LM; Chan WC
Clin Cancer Res; 2009 Sep; 15(17):5494-502. PubMed ID: 19706817
[TBL] [Abstract][Full Text] [Related]
22. Interleukin-6 plasma levels are modulated by a polymorphism in the NF-κB1 gene and are associated with outcome following rituximab-combined chemotherapy in diffuse large B-cell non-Hodgkin lymphoma.
Giachelia M; Voso MT; Tisi MC; Martini M; Bozzoli V; Massini G; D'Aló F; Larocca LM; Leone G; Hohaus S
Leuk Lymphoma; 2012 Mar; 53(3):411-6. PubMed ID: 21902578
[TBL] [Abstract][Full Text] [Related]
23. Lymphoma cell VEGFR2 expression detected by immunohistochemistry predicts poor overall survival in diffuse large B cell lymphoma treated with immunochemotherapy (R-CHOP).
Gratzinger D; Advani R; Zhao S; Talreja N; Tibshirani RJ; Shyam R; Horning S; Sehn LH; Farinha P; Briones J; Lossos IS; Gascoyne RD; Natkunam Y
Br J Haematol; 2010 Jan; 148(2):235-44. PubMed ID: 19821819
[TBL] [Abstract][Full Text] [Related]
24. Prognostic impact of activated B-cell focused classification in diffuse large B-cell lymphoma patients treated with R-CHOP.
Nyman H; Jerkeman M; Karjalainen-Lindsberg ML; Banham AH; Leppä S
Mod Pathol; 2009 Aug; 22(8):1094-101. PubMed ID: 19448593
[TBL] [Abstract][Full Text] [Related]
25. MicroRNAs are independent predictors of outcome in diffuse large B-cell lymphoma patients treated with R-CHOP.
Alencar AJ; Malumbres R; Kozloski GA; Advani R; Talreja N; Chinichian S; Briones J; Natkunam Y; Sehn LH; Gascoyne RD; Tibshirani R; Lossos IS
Clin Cancer Res; 2011 Jun; 17(12):4125-35. PubMed ID: 21525173
[TBL] [Abstract][Full Text] [Related]
26. Diffuse large B-cell lymphomas with CDKN2A deletion have a distinct gene expression signature and a poor prognosis under R-CHOP treatment: a GELA study.
Jardin F; Jais JP; Molina TJ; Parmentier F; Picquenot JM; Ruminy P; Tilly H; Bastard C; Salles GA; Feugier P; Thieblemont C; Gisselbrecht C; de Reynies A; Coiffier B; Haioun C; Leroy K
Blood; 2010 Aug; 116(7):1092-104. PubMed ID: 20435884
[TBL] [Abstract][Full Text] [Related]
27. CD40 is a potential marker of favorable prognosis in patients with diffuse large B-cell lymphoma treated with immunochemotherapy.
Rydström K; Linderoth J; Nyman H; Ehinger M; Joost P; Bendahl PO; Leppä S; Jerkeman M
Leuk Lymphoma; 2010 Sep; 51(9):1643-8. PubMed ID: 20593977
[TBL] [Abstract][Full Text] [Related]
28. Potentially oncogenic B-cell activation-induced smaller isoforms of FOXP1 are highly expressed in the activated B cell-like subtype of DLBCL.
Brown PJ; Ashe SL; Leich E; Burek C; Barrans S; Fenton JA; Jack AS; Pulford K; Rosenwald A; Banham AH
Blood; 2008 Mar; 111(5):2816-24. PubMed ID: 18077790
[TBL] [Abstract][Full Text] [Related]
29. Cell of origin fails to predict survival in patients with diffuse large B-cell lymphoma treated with autologous hematopoietic stem cell transplantation.
Gu K; Weisenburger DD; Fu K; Chan WC; Greiner TC; Aoun P; Smith LM; Bast M; Liu Z; Bociek RG; Bierman PJ; Armitage JO; Vose JM
Hematol Oncol; 2012 Sep; 30(3):143-9. PubMed ID: 22009820
[TBL] [Abstract][Full Text] [Related]
30. Immunoblastic morphology but not the immunohistochemical GCB/nonGCB classifier predicts outcome in diffuse large B-cell lymphoma in the RICOVER-60 trial of the DSHNHL.
Ott G; Ziepert M; Klapper W; Horn H; Szczepanowski M; Bernd HW; Thorns C; Feller AC; Lenze D; Hummel M; Stein H; Müller-Hermelink HK; Frank M; Hansmann ML; Barth TF; Möller P; Cogliatti S; Pfreundschuh M; Schmitz N; Trümper L; Loeffler M; Rosenwald A
Blood; 2010 Dec; 116(23):4916-25. PubMed ID: 20736456
[TBL] [Abstract][Full Text] [Related]
31. The expression of the endoplasmic reticulum stress sensor BiP/GRP78 predicts response to chemotherapy and determines the efficacy of proteasome inhibitors in diffuse large b-cell lymphoma.
Mozos A; Roué G; López-Guillermo A; Jares P; Campo E; Colomer D; Martinez A
Am J Pathol; 2011 Nov; 179(5):2601-10. PubMed ID: 21907693
[TBL] [Abstract][Full Text] [Related]
32. Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma.
Dunleavy K; Pittaluga S; Czuczman MS; Dave SS; Wright G; Grant N; Shovlin M; Jaffe ES; Janik JE; Staudt LM; Wilson WH
Blood; 2009 Jun; 113(24):6069-76. PubMed ID: 19380866
[TBL] [Abstract][Full Text] [Related]
33. Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways.
Lenz G; Wright GW; Emre NC; Kohlhammer H; Dave SS; Davis RE; Carty S; Lam LT; Shaffer AL; Xiao W; Powell J; Rosenwald A; Ott G; Muller-Hermelink HK; Gascoyne RD; Connors JM; Campo E; Jaffe ES; Delabie J; Smeland EB; Rimsza LM; Fisher RI; Weisenburger DD; Chan WC; Staudt LM
Proc Natl Acad Sci U S A; 2008 Sep; 105(36):13520-5. PubMed ID: 18765795
[TBL] [Abstract][Full Text] [Related]
34. PTEN tumor suppressor plays less prognostic role than P53 tumor suppressor in diffuse large B-cell lymphoma.
Liu YY; Yao SN; Zhao Y; Yao ZH; Ma J; Xia QX; Fu K; Yang SJ
Leuk Lymphoma; 2010 Sep; 51(9):1692-8. PubMed ID: 20807096
[TBL] [Abstract][Full Text] [Related]
35. High levels of topoisomerase IIalpha protein expression in diffuse large B-cell lymphoma are associated with high proliferation, germinal center immunophenotype, and response to treatment.
Pentheroudakis G; Goussia A; Voulgaris E; Nikolaidis K; Ioannidou E; Papoudou-Bai A; Grepi K; Kanavaros P; Pavlidis N; Bai M
Leuk Lymphoma; 2010 Jul; 51(7):1260-8. PubMed ID: 20497003
[TBL] [Abstract][Full Text] [Related]
36. Stromal gene signatures in large-B-cell lymphomas.
Lenz G; Wright G; Dave SS; Xiao W; Powell J; Zhao H; Xu W; Tan B; Goldschmidt N; Iqbal J; Vose J; Bast M; Fu K; Weisenburger DD; Greiner TC; Armitage JO; Kyle A; May L; Gascoyne RD; Connors JM; Troen G; Holte H; Kvaloy S; Dierickx D; Verhoef G; Delabie J; Smeland EB; Jares P; Martinez A; Lopez-Guillermo A; Montserrat E; Campo E; Braziel RM; Miller TP; Rimsza LM; Cook JR; Pohlman B; Sweetenham J; Tubbs RR; Fisher RI; Hartmann E; Rosenwald A; Ott G; Muller-Hermelink HK; Wrench D; Lister TA; Jaffe ES; Wilson WH; Chan WC; Staudt LM;
N Engl J Med; 2008 Nov; 359(22):2313-23. PubMed ID: 19038878
[TBL] [Abstract][Full Text] [Related]
37. Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells.
Davis RE; Brown KD; Siebenlist U; Staudt LM
J Exp Med; 2001 Dec; 194(12):1861-74. PubMed ID: 11748286
[TBL] [Abstract][Full Text] [Related]
38. Gene-expression profiling and not immunophenotypic algorithms predicts prognosis in patients with diffuse large B-cell lymphoma treated with immunochemotherapy.
Gutiérrez-García G; Cardesa-Salzmann T; Climent F; González-Barca E; Mercadal S; Mate JL; Sancho JM; Arenillas L; Serrano S; Escoda L; Martínez S; Valera A; Martínez A; Jares P; Pinyol M; García-Herrera A; Martínez-Trillos A; Giné E; Villamor N; Campo E; Colomo L; López-Guillermo A;
Blood; 2011 May; 117(18):4836-43. PubMed ID: 21441466
[TBL] [Abstract][Full Text] [Related]
39. Identification of biological markers of sensitivity to high-clinical-risk-adapted therapy for patients with diffuse large B-cell lymphoma.
Saez AI; García-Cosío M; Sáez AJ; Hernández JM; Sánchez-Verde L; Alvarez D; de la Cueva P; Arranz R; Conde E; Grande C; Rodríguez J; Caballero D; Piris MA
Leuk Lymphoma; 2009 Apr; 50(4):571-81. PubMed ID: 19373655
[TBL] [Abstract][Full Text] [Related]
40. Akt, 14-3-3ζ, and vimentin mediate a drug-resistant invasive phenotype in diffuse large B-cell lymphoma.
Maxwell SA; Cherry EM; Bayless KJ
Leuk Lymphoma; 2011 May; 52(5):849-64. PubMed ID: 21323512
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
